Sergio Mayor Torroglosa-rekin lankidetzan egindako argitalpenak (11)

2010

  1. Ocular hypertension impairs optic nerve axonal transport leading to progressive retinal ganglion cell degeneration

    Experimental Eye Research, Vol. 90, Núm. 1, pp. 168-183

2009

  1. A computerized analysis of the entire retinal ganglion cell population and its spatial distribution in adult rats

    Vision Research, Vol. 49, Núm. 1, pp. 115-126

  2. Retinal ganglion cell population in adult albino and pigmented mice: A computerized analysis of the entire population and its spatial distribution

    Vision Research, Vol. 49, Núm. 6, pp. 637-647

2007

  1. Neuroprotection of retinal ganglion cell function and their central nervous system targets

    Eye (Basingstoke), Vol. 21, pp. S42-S45

2005

  1. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: Neuroprotection with brimonidine

    Investigative Ophthalmology and Visual Science, Vol. 46, Núm. 10, pp. 3825-3835

2003

  1. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: Long-term neuroprotection with brimonidine

    Experimental Neurology, Vol. 184, Núm. 2, pp. 767-777

2002

  1. Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: A dose response in vivo study

    Experimental Eye Research, Vol. 74, Núm. 2, pp. 181-189

  2. Retinal ganglion cell death after acute retinal ischemia is an ongoing process whose severity and duration depends on the duration of the insult

    Neuroscience, Vol. 109, Núm. 1, pp. 157-168

  3. Transient ischemia of the retina results in altered retrograde axoplasmic transport: Neuroprotection with brimonidine

    Experimental Neurology, Vol. 178, Núm. 2, pp. 243-258

2001

  1. Brimonidine's neuroprotective effects against transient ischaemia-induced retinal ganglion cell death

    European Journal of Ophthalmology

  2. Retinal ganglion cell death induced by retinal ischemia: Neuroprotective effects of two alpha-2 agonists

    Survey of Ophthalmology, Vol. 45, Núm. 6